Open access
Open access
Powered by Google Translator Translator

All Posts

Introducing IntelliDoctor: The Future of Medical Inquiry for Medical Professionals

26 Feb, 2024 | 11:21h | UTC

We are thrilled to introduce IntelliDoctor, an innovative platform designed specifically for medical professionals, aiming to revolutionize the way medical inquiries are addressed. At IntelliDoctor, we understand the critical need for accurate, timely, and evidence-based information in the medical field. Our platform leverages advanced AI technology, including sophisticated prompt engineering and Retrieval Augmented Generation (RAG), to provide precise answers to clinical questions.

IntelliDoctor’s core mission is to support healthcare professionals by delivering real-time academic insights. Our AI system meticulously searches open academic sources to offer reliable responses based on verifiable research. This process ensures that every answer we provide is not only immediate but also grounded in credible data, with a typical response time of 10-15 seconds.

Our platform is user-friendly and designed to be accessible to medical professionals worldwide. Currently available in English (https://www.intellidoctor.ai/en) and Portuguese (https://www.intellidoctor.ai/pt), IntelliDoctor welcomes users to experience its capabilities in any language, adapting to the global nature of the medical community. For a limited time, we are offering free access to our platform, allowing medical professionals to explore and benefit from our advanced AI-driven solutions.

Getting started with IntelliDoctor is straightforward: no personal information is required, just a Gmail account. We invite you to join us in this medical revolution, where AI technology meets clinical expertise to enhance patient care and support medical professionals. Experience the future of medical inquiry with IntelliDoctor and be part of the transformation in healthcare innovation.


AI-Powered GPTs for Doctors: Evidence-Based Medicine & Clinical Decision Support Prompts

17 Dec, 2023 | 18:39h | UTC

Welcome to IntelliDoctor’s innovative collection of AI-Powered GPT Prompts, specifically designed for doctors seeking to enhance their clinical practice with evidence-based information. Utilizing the latest Natural Language Processing (NLP) technology, our prompts provide decisive support in various aspects of medicine, from identifying drug interactions to differential diagnoses, treatments, and more. Each prompt has been meticulously developed to provide accurate and up-to-date information, assisting healthcare professionals in quickly accessing crucial data for patient care decision-making. Important: access to these specialized prompts requires a GPT-4 subscription. With our tool, doctors can easily obtain relevant clinical insights, optimizing time and improving the quality of medical care. Explore our 6 specialized prompts and discover how artificial intelligence can transform your medical practice.

Disclaimer: These tools are intended for use by doctors and healthcare professionals only, and are not recommended for use by other individuals. GPT models can make errors, so please use them with extreme caution and always verify the information before applying it to patient care.

 

  1. All Purpose: Comprehensive solutions for general medical inquiries.

 

  1. Medications: Detailed information on various medications.

 

  1. Interactions: Analysis of potential drug interactions.

 

  1. Diseases: Information on a wide range of diseases.

 

  1. Signs and Symptoms: Assistance in interpreting clinical signs and symptoms.

 

  1. Differential Diagnosis: A tool to aid in differential diagnosis.

 


RCT: No difference in ICU length of stay or 90-day mortality between tight and liberal glucose control

2 Oct, 2023 | 11:25h | UTC

Study Design and Population: This randomized controlled trial assessed the effects of tight versus liberal glucose control on the length of ICU stay in critically ill patients. A total of 9,230 patients were included, with 4,622 in the liberal-control group (insulin initiation when blood glucose levels exceeded 215 mg/dL) and 4,608 in the tight-control group (blood glucose targeted between 80 and 110 mg/dL). In both groups, parenteral nutrition was withheld during the first week of ICU admission. The primary endpoint was the duration of ICU stay, and 90-day mortality served as a key safety outcome.

Main Findings: No significant differences were observed in the primary endpoint, the length of ICU stay, between the two groups (hazard ratio 1.00; 95% CI, 0.96 to 1.04; P=0.94). The 90-day mortality rates were also similar (10.1% in the liberal-control group vs. 10.5% in the tight-control group, P=0.51). Incidences of severe hypoglycemia were low and statistically similar in both groups (1.0% in the tight-control group vs. 0.7% in the liberal-control group). Secondary outcomes, including new infections and the duration of respiratory and hemodynamic support, showed no significant differences. However, lower incidences of severe acute kidney injury and cholestatic liver dysfunction were observed in the tight-control group.

Implications & Limitations: The study supports existing evidence that tight glucose control doesn’t provide substantial benefits in reducing ICU stay duration or mortality. This suggests that a more liberal approach to glucose control may be preferable in most ICU settings, especially to minimize hypoglycemia risk. Key limitations of the study include its narrow focus on the absence of early parenteral nutrition, which could limit generalizability, and the inability to blind caregivers to treatment assignments. Future research should investigate the impact of tight glucose control in various patient subgroups and under different nutritional conditions.

Article: Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU – New England Journal of Medicine

 


RCT: Propafenone leads to quicker sinus rhythm restoration than amiodarone in supraventricular arrhythmias related to septic shock

1 Oct, 2023 | 15:19h | UTC

Study Design & Population: The research was a two-center, prospective, controlled parallel-group, double-blind trial involving 209 septic shock patients who had new-onset supraventricular arrhythmia and a left ventricular ejection fraction above 35%. Patients were randomized to receive either intravenous propafenone (70 mg bolus followed by 400–840 mg/24 h) or amiodarone (300 mg bolus followed by 600–1800 mg/24 h).

Main Findings: The primary outcomes focused on the proportion of patients in sinus rhythm 24 hours post-infusion, time to the first sinus rhythm restoration, and arrhythmia recurrence rates. No significant difference was observed in 24-hour sinus rhythm rates between the propafenone (72.8%) and amiodarone (67.3%) groups (p=0.4). Time to the first rhythm restoration was significantly shorter for the propafenone group (median 3.7 hours) compared to the amiodarone group (median 7.3 hours, p=0.02). Recurrence of arrhythmia was notably lower in the propafenone group (52%) than in the amiodarone group (76%, p<0.001). In the subgroup of patients with a dilated left atrium, amiodarone appeared to be more effective.

Implications & Limitations: The study suggests that while propafenone doesn’t offer better rhythm control at 24 hours compared to amiodarone, it does provide faster cardioversion and fewer arrhythmia recurrences, especially in patients with a non-dilated left atrium. No significant differences were observed in clinical outcomes, such as ICU or long-term mortality, between propafenone and amiodarone in the trial. Limitations include potential underpowering of the study and the inability to fully account for the impact of multiple covariates involved in the complex therapy of septic shock.

Article: Balik, M., Maly, M., Brozek, T. et al. Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial. Intensive Care Med (2023)

 

Commentary on Twitter:

 


LinksMedicus.com: operations paused for the foreseeable future.

23 Aug, 2023 | 12:44h | UTC

Dear LinksMedicus Subscribers,

I regret to inform you that LinksMedicus.com will be pausing operations for the foreseeable future. After 12 years and over 30.000 curated articles in all specialties, I will now focus on my clinical practice.

Best regards to all.

 

Euclides Cavalcanti

São Paulo, Brazil

euclidesfac@gmail.com

 


Crossover RCT | Using one-size cuff results in major inaccuracy in BP readings across varying arm sizes

11 Aug, 2023 | 15:41h | UTC

Effects of Cuff Size on the Accuracy of Blood Pressure Readings: The Cuff(SZ) Randomized Crossover Trial – JAMA Internal Medicine (free for a limited period)

Commentaries:

When it comes to blood pressure cuffs, size matters – MedicalResearch.com

One-size-fits-all blood pressure cuffs ‘strikingly inaccurate,’ study says – CNN

Related:

Brief Review | Why is cuff size so important and other factors that affect accurate blood pressure measurement

[News release – not published yet] Study finds blood pressure cuff size matters, affects blood pressure readings

 

Commentary on Twitter

 


Perspective | Clinicians debate the usefulness of NAFLD name change

11 Aug, 2023 | 15:39h | UTC

Clinicians debate the usefulness of NAFLD name change – MDedge

Original article: From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization

 


Presented at ASRS Meeting | Studies link GLP-1 agonists to progression of diabetic retinopathy

11 Aug, 2023 | 15:38h | UTC

Studies link GLP-1 agonists to progression of diabetic retinopathy – MDedge

 


Study | The high financial and human cost of quality metric reporting in hospitals

11 Aug, 2023 | 15:36h | UTC

The Volume and Cost of Quality Metric Reporting – JAMA (link to abstract – $ for full-text)

Author Interview: The Costs of Quality Reporting – JAMA

Commentaries:

The Cost of “Quality” – Emergency Medicine Literature of Note

How John Hopkins spent $5m and 108,478 hours on quality reporting in one year – HealthLeaders

The cost of quality metric reporting – Becker’s Hospital Review

 


Study | Uncovering the potential overuse of laboratory tests by combining cost, abnormal result proportion, and physician variation

11 Aug, 2023 | 15:34h | UTC

Data-driven approach to identifying potential laboratory overuse in general internal medicine (GIM) inpatients – BMJ Open Quality

 


Guideline | Closure of laparotomy in emergency settings

11 Aug, 2023 | 15:33h | UTC

ECLAPTE: Effective Closure of LAParoTomy in Emergency—2023 World Society of Emergency Surgery guidelines for the closure of laparotomy in emergency settings – World Journal of Emergency Surgery

 


ERS statement on protracted bacterial bronchitis in children

11 Aug, 2023 | 15:32h | UTC

ERS statement on protracted bacterial bronchitis in children – European Respiratory Journal

 


Perspective | AI predicted to play major role in cardiac CT and CV care in the coming decade

11 Aug, 2023 | 15:30h | UTC

AI Predicted to Play Major Role in Cardiac CT and CV Care in the Coming Decade – TCTMD

 


M-A | Pharmacist-led home BP telemonitoring enhances control over usual care

11 Aug, 2023 | 15:29h | UTC

Adding Pharmacist-Led Home Blood Pressure Telemonitoring to Usual Care for Blood Pressure Control: A Systematic Review and Meta-Analysis – American Journal of Cardiology

 


RCT | Superior PFS with avelumab vs. chemotherapy in second-line treatment for mCRC with microsatellite instability

11 Aug, 2023 | 15:25h | UTC

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial – JAMA Oncology

See also: Visual Abstract

Commentary: Avelumab Outperforms Standard Second-Line Therapy in dMMR/MSI Metastatic CRC – Cancer Therapy Advisor

 


Review | An approach to non-left main bifurcation lesions

11 Aug, 2023 | 15:22h | UTC

An Approach to Non-left Main Bifurcation Lesions: A Contemporary Review – US Cardiology Review

 

Commentary on Twitter

 


Cohort Study | Mortality risk in anti-MDA5 dermatomyositis linked to rapid ILD progression and anti-Ro52 antibody levels

11 Aug, 2023 | 15:21h | UTC

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody – Arthritis Research & Therapy

 

Commentary on Twitter

 


Systematic Review | Poor handling of continuous predictors in clinical prediction models using logistic regression

11 Aug, 2023 | 15:19h | UTC

Poor handling of continuous predictors in clinical prediction models using logistic regression: a systematic review – Journal of Clinical Epidemiology

 


RCT – 2ry analysis | Aerobic exercise intervention shows potential to reduce chemotherapy-induced peripheral neuropathy

11 Aug, 2023 | 15:17h | UTC

Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

Commentary: Aerobic Exercise Cuts Chemotherapy-Induced Peripheral Neuropathy Symptoms – HealthDay

 

Commentary on Twitter

 


Cohort Study | Younger age at hypertrophic cardiomyopathy diagnosis, male sex among predictors of developing LV systolic dysfunction

11 Aug, 2023 | 15:16h | UTC

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry – Circulation

 

Commentary on Twitter

 


RCT | Field sobriety tests display insufficient accuracy for detecting THC-specific driving impairment

11 Aug, 2023 | 15:14h | UTC

Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial – JAMA Psychiatry

See also: Visual Abstract

News Release: Can field sobriety tests identify drivers under the influence of cannabis? – University of California – San Diego

Commentary: Trained Officers Using Current Field Sobriety Tests May Misclassify Cannabis-Impaired Drivers – Psychiatric News Alert

 

Commentary on Twitter

 


Cohort Study | U-shaped relationship between BMI and mortality in heart failure patients

11 Aug, 2023 | 15:12h | UTC

Body mass index and survival in people with heart failure – Heart

 

Commentary on Twitter

 


Survival ≠ Recovery | A narrative review of post-intensive care syndrome

11 Aug, 2023 | 15:11h | UTC

Survival ≠ Recovery: A Narrative Review of Post-Intensive Care Syndrome – CHEST Critical Care

 


Review | Primary ciliary dyskinesia

11 Aug, 2023 | 15:10h | UTC

Primary Ciliary Dyskinesia – CHEST Pulmonary

 


RCT | Restrictive vs. liberal red blood cell transfusion strategy for critically injured patients

11 Aug, 2023 | 15:08h | UTC

The Restrictive Red Blood Cell Transfusion Strategy for Critically Injured Patients (RESTRIC) trial: a cluster-randomized, crossover, non-inferiority multicenter trial of restrictive transfusion in trauma – Journal of Intensive Care

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.